



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GW280264X

Cat. No.:	HY-115670
CAS No.:	866924-39-2
Molecular Formula:	C ₂₈ H ₄₁ N ₅ O ₆ S
Molecular Weight:	575.72
Target:	MMP
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (217.12 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.7370 mL	8.6848 mL	17.3696 mL
		5 mM		0.3474 mL	1.7370 mL	3.4739 mL
		10 mM		0.1737 mL	0.8685 mL	1.7370 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.61 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC ₅₀ s of 8.0 nM and 11.5 nM, respectively ^[1] . ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells ^[2] .	
IC ₅₀ & Target	ADAM17 8 nM (IC ₅₀)	ADAM10 11.5 nM (IC ₅₀)
In Vitro	The proliferation of GS-7 cells was significantly reduced upon treatment with GW280264X or ADAM10/17 co-knockdown ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Cell Viability Assay ^[2]	
	Cell Line:	Glioblastoma-initiating cells (GIC) GS-7 cells

Concentration:	0.1, 1, and 3 μ M
Incubation Time:	48 hours
Result:	Proliferation of GIC is inhibited through inhibition of ADAM10 and ADAM17.

In Vivo

Pharmacological inhibition of ADAM10 and ADAM17 improves functional recovery after spinal cord injury (SCI)^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice ^[3]
Dosage:	100 μ g/kg
Administration:	I.p. injected; every day for one week starting 4 h post-surgery
Result:	Showed significantly improved functional recovery compared to the control group.

CUSTOMER VALIDATION

- Research Square Preprint. 2023 Nov 23.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Christian Hundhausen, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood*. 2003 Aug 15;102(4):1186-95.
- [2]. Fabian Wolpert, et al. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. *Neuro Oncol*. 2014 Mar;16(3):382-91.
- [3]. Daniela Sommer, et al. ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury. *Brain Behav Immun*. 2019 Aug;80:129-145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA